IMAX Corporation IMAX

Morgan Stanley started coverage on IMAX with an Overweight rating and a $63 price target, signaling more than 18% upside from the prior close as the stock rose about 1.7%. The firm says IMAX is becoming central to the moviegoing experience, with its expanding screen network and growing film slate creating a cycle of more screens, more releases and higher box-office revenue. Morgan Stanley and others project global IMAX box office rising from about $1.5 billion in 2026 to roughly $1.6–$1.7 billion by 2027–2028. Nine of 11 analysts tracked by Koyfin rate IMAX Buy or Strong Buy. The Odyssey, shot entirely on IMAX film, is cited as a catalyst underscoring premium demand and the value of IMAX technology. Stocktwits sentiment has shifted toward bullish, and IMAX has gained more than 42% year-to-date. Overweight stance with a $63 target signals sizable upside from IMAX's screen-network expansion and premium-content strategy.

StockStory flags IMAX as a profitable pick with solid fundamentals. IMAX posts trailing 12-month GAAP operating margin of 20.2%, about 17.9% five-year revenue growth, and a 24.8-point expansion in free cash flow margin, with returns on capital trending higher. At $54.44, the stock trades around 26x forward P/E, supported by strong growth and cash flow that fund investments, buybacks, and dividends. The piece notes market-share gains and improving returns on capital. It also covers Carlisle to sell due to flat organic growth and weaker earnings, and Cigna to watch because of large revenue scale and growing sales. A full free research report is offered to assess buy timing. Strong fundamentals and favorable valuation cited, but no new catalysts or near-term triggers to significantly shift IMAX's trajectory.

IMAX (IMAX) has outpaced its Consumer Discretionary peers so far this year, rising about 45% year-to-date while the sector declines roughly 13.6%. The stock carries a Zacks Rank of #2 (Buy) and has seen the full-year earnings consensus boosted about 15.3% over the last three months, signaling improving sentiment. Within the sector, IMAX sits in the Film and Television Production and Distribution industry (8 stocks) and is ahead of its group, which has gained around 5.3% YTD. Madison Square Garden Entertainment (MSGE) has also outperformed, up about 48.8% YTD, and sports a #1 (Strong Buy) with a 6.3% EPS estimate increase over three months. MSGE is in the Media Conglomerates industry, which trails the market (-12.9% YTD). The piece suggests investors continue to watch IMAX and MSGE for potential continued strength. IMAX shows notable outperformance vs. its sector and improving earnings sentiment, implying a moderate near-term upside with balanced risks.

IMAX has surged 40.5% over six months to $53.47, driven by solid results. A StockStory piece highlights three positives: 17.9% annualized revenue growth over the past five years (above the average business services firm), a 24.8-point expansion in free cash flow margin with free cash flow margin at 24% trailing twelve months, and rising ROIC indicating a strengthening competitive edge. The stock trades around 25.6x forward earnings. The piece promotes a free comprehensive research report to gauge whether now is a good time to buy. Positive fundamentals and favorable valuation suggest modest near-term upside, but no transformative catalysts are presented.

IMAX shares rose 2.6% after 'Resident Evil' opened strong, with the company forecasting US$1.4 billion in worldwide box office in 2026. Year-to-date stock return ~50%, one-year ~65%, while three- and five-year TSR ~179% and ~192% indicate momentum. Analysts note IMAX is trading near a fair value of about $55.65 vs $54.04 close, suggesting limited upside beyond expectations. The company’s diversification into local-language films, alternative content, and partnerships with Apple, Amazon, Netflix aims to lift margins and per-screen contribution, potentially buffering earnings against cinema declines. However risks include home entertainment cannibalization and a thinner blockbuster slate. Valuation remains premium: P/E ~72x vs peers ~21x; the gap could be cushion or cliff if expectations reset. Forecasted 2026 box office and diversification could moderately boost earnings, but high valuation and risks limit upside.

IMAX's worldwide box-office forecast benefited from a franchise-record opening of Resident Evil, reinforcing the premium-format demand thesis and supporting ongoing expansion into higher-value experiences. Q2 2026 results showed revenue of $102.84 million and net income of $15.4 million, underscoring how strong titles can translate into earnings. The company is pursuing network expansions in India and the Southeastern U.S. to capitalize on box-office momentum. Yet the narrative notes IMAX remains vulnerable to blockbuster-driven cycles and shifting consumer habits, limiting upside. IMAX projects $505.9 million revenue and $95.8 million earnings by 2029, with about 6.7% annual revenue growth and a fair value around $55.65, though bear cases exist. Overall, the development reinforces the near-term premium-format investment story while leaving long-term risks largely unresolved. Strong near-term catalyst from a blockbuster opening reinforces premium-format demand, but long-term risk remains due to dependence on blockbuster releases and consumer shifts.

IMAX reports its highest grossing summer ever at $728 million worldwide, up 73% from the previous record. Record summer box office performance drives revenue growth and strengthens IMAX competitive standing.

Demand for “The Odyssey” is pushing IMAX Corporation shares higher. Demand surge for one film lifts near-term stock price but does not alter long-term company trajectory.

IMAX achieved $47 million global box office over the weekend, powered by the strong China opening of Christopher Nolan’s The Odyssey. Strong single-weekend box office lifts near-term revenue and sentiment without altering long-term trajectory.

IMAX accounted for RMB 90 million (USD 13.2 million), or 45% of opening weekend box office, for Christopher Nolan's The Odyssey in China. Strong IMAX share in one major film release supports near-term revenue visibility without altering long-term company trajectory.

Christopher Nolan’s The Odyssey achieves the highest grossing IMAX release ever at $289 million and rising. Record IMAX gross from major Nolan film strengthens brand visibility and admissions outlook.

IMAX stock rose on Monday after the company reported stronger-than-expected quarterly results and raised its full-year box office revenue outlook. Better earnings and raised guidance can lift near-term sentiment and valuation but are unlikely to reshape the company's long-term trajectory.

IMAX CEO delivers strong statements to investors while praising director Christopher Nolan. CEO comments on Nolan point to ongoing major film collaborations that may support IMAX revenue.

IMAX Corporation achieved an all-time monthly box office record, powered by The Odyssey's performance and resulting in historic growth. All-time box office record and historic growth directly boost revenue outlook and investor sentiment for IMAX.

IMAX stock soared on Monday. Stock price surge signals moderate positive market reaction potentially influencing near-term sentiment.

IMAX stock reaches all-time high as CEO states demand for ‘The Odyssey’ continues to defy gravity. Strong demand commentary for major release lifts stock to record high with moderate short-term revenue implications.

Christopher Nolan’s The Odyssey drove IMAX to its highest grossing month in company history with $257 million in July. Record monthly revenue highlights strong demand for IMAX screens but reflects single-film performance rather than structural change.

IMAX expands Sony Pictures’ Spider-Man: Brand New Day screenings across North America from August 6. Major film expansion in IMAX format increases theater utilization and ticket premiums.

"Spider-Man: Brand New Day" generated $19.2 million in IMAX ticket sales during its opening weekend in China and established new franchise records. Strong China IMAX box office for a major film supports positive market sentiment but represents limited overall impact on company trajectory.

IMAX Corporation stock price continues rising on sustained positive momentum from box office results and theater expansions. Ongoing stock gains signal moderately improved market sentiment without evidence of major strategic shifts.

AMC reports record IMAX ticket sales following strong opening for The Odyssey. Record AMC ticket sales signal strong IMAX demand and positive market momentum.

IMAX stock outperformed the market on Monday, driven by positive company-specific developments that lifted investor sentiment and share price. Single-day stock outperformance indicates moderate short-term positive sentiment without evidence of fundamental long-term shifts.

IMAX reports record-breaking $48 million second weekend for Christopher Nolan’s The Odyssey. Strong box office for major IMAX releases supports short-term revenue and brand visibility without altering long-term company trajectory.

IMAX shares rose 10.5% after Q2 profit increase and new automotive deal expanding operations beyond theaters. Q2 profit growth plus automotive partnership marks major strategic expansion with potential to alter long-term trajectory.

IMAX launches its first branded in-vehicle entertainment system, expanding from cinemas into automotive applications. New in-vehicle system launch represents moderate diversification with limited but noticeable effects on growth trajectory.

IMAX posted a Q2 earnings beat alongside the Odyssey debut, prompting questions on whether shares are now fully valued. Q2 beat and Odyssey debut create moderate influence on IMAX financials and positioning without guaranteed long-term trajectory shift.

IMAX stock eyes second weekly gain as Wall Street reassesses growth outlook due to 'The Odyssey' moment. Wall Street reassessment of IMAX growth outlook tied to 'The Odyssey' signals significant shift in investor sentiment and trajectory.

IMAX shares rose 12% after the company beat Q2 earnings expectations with year-over-year revenue growth. Q2 earnings beat produced immediate 12% stock gains but reflects standard financial results without shifting long-term strategy or market position.

IMAX Corporation held its Q2 2026 earnings call covering quarterly financial results, revenue, net income, and forward business outlook. Quarterly earnings updates provide financial performance details that moderately affect near-term stock valuation and sentiment.

IMAX Corporation stock rose 11.86% after beating earnings expectations and signaling optimism for the second half. Earnings beat combined with H2 optimism drives sharp share price gains and signals improved performance outlook.